Linalool
CAT:
804-HY-N0368-01
Size:
1 g
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Linalool
- CAS Number: 78-70-6
- UNSPSC Description: Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities[1][2][3][4][5].
- Target Antigen: Apoptosis; Bacterial; Endogenous Metabolite; iGluR; TNF Receptor
- Type: Natural Products
- Related Pathways: Anti-infection;Apoptosis;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling
- Applications: Cancer-programmed cell death
- Field of Research: Cancer; Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
- Assay Protocol: https://www.medchemexpress.com/linalool.html
- Purity: 99.11
- Solubility: DMSO : 100 mg/mL (ultrasonic)
- Smiles: C=CC(O)(C)CC/C=C(C)/C
- Molecular Weight: 154.253
- References & Citations: [1]Oner Z1, et al. The protective and therapeutic effects of linalool against doxorubicin-induced cardiotoxicity in Wistar albino rats. Hum Exp Toxicol. 2019 Apr 12:960327119842634.|[2]Jun HJ, et al. Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.|[3]Jana S, et al. Antitumorigenic potential of linalool is accompanied by modulation of oxidative stress: an in vivo study in sarcoma-180 solid tumor model. Nutr Cancer. 2014;66(5):835-48. |[4]Rodenak-Kladniew B, et al. Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells. Heliyon. 2020 Dec 15;6(12):e05639. |[5]An Q, et al. Recent updates on bioactive properties of linalool. Food Funct. 2021 Nov 1;12(21):10370-10389.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: No Development Reported